Dac51 also has a synergistic effect with anti‐PD‐L1 immunotherapy in halting tumor growth, showing its promise to overcome cancer cell resistance to anti‐PD‐L1 therapy.[140] Meanwhile, Huff et al. This evidence concerns the gene CD274 and neoplasm.